Legend Biotech Corp LEGN.OQ LEGN.O is expected to show a rise in quarterly revenue when it reports results on March 10 for the period ending December 31 2025
The Somerset New Jersey-based company is expected to report a 64.5% increase in revenue to $306.875 million from $186.52 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Legend Biotech Corp is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Legend Biotech Corp is $69.50, about 291.5% above its last closing price of $17.75
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.10 | -0.08 | -0.22 | Missed | -160.5 |
Jun. 30 2025 | -0.08 | -0.14 | -0.68 | Missed | -375.5 |
Mar. 31 2025 | -0.19 | -0.22 | -0.54 | Missed | -142.2 |
Dec. 31 2024 | -0.34 | -0.31 | 0.15 | Beat | 148 |
Sep. 30 2024 | -0.42 | -0.41 | -0.68 | Missed | -67 |
Jun. 30 2024 | -0.41 | -0.36 | -0.10 | Beat | 72.2 |
Mar. 31 2024 | -0.35 | -0.31 | -0.32 | Missed | -4.5 |
Dec. 31 2023 | -0.94 | -0.70 | -0.80 | Missed | -14.3 |
This summary was machine generated March 6 at 13:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)